Argenx SE - American Depositary Receipt

Argenx SE, through its American Depositary Receipt (ADR), allows investors in the United States to hold shares in the Belgian biopharmaceutical company without dealing directly in foreign stock markets. ADRs are traded on U.S. exchanges, representing a specified number of shares in a foreign corporation, and provide shareholders with potential dividends, shares of the equity, and other financial benefits similar to ordinary shares. Argenx SE operates in the biotech sector, specializing in the development of antibody-based therapies for the treatment of severe autoimmune diseases and cancer. With its ADR, Argenx SE aims to broaden its shareholder base, providing U.S. investors with easier access to its innovative, clinically-oriented research and developments. The ADR serves as a bridge connecting American investors to European biotechnology innovations, contributing to the diversification of global investment portfolios, and enhancing marketability and liquidity of its shares within the U.S. financial markets.